Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Long-Term Durable FVIII Expression with Improvements in Bleeding Rates Following AAV-Mediated FVIII Gene Transfer for Hemophilia A: Multiyear Follow-up on the Phase I/II Trial of SPK-8011

Blood (2022) 140 (Supplement 1): 1899–1901.

https://doi.org/10.1182/blood-2022-158903

Published: 2022

Journal Articles

Rapid Clearance of Vector Following AAV-Mediated FVIII Gene Transfer in the Phase I/II Trial of SPK-8011 in People with Hemophilia A

Huyen Tran, M. Elaine Eyster, Stacy E. Croteau, Margaret V. Ragni, Benjamin J. Samelson-Jones, Spencer Sullivan, John E.J. Rasko, Kristen Jaworski, Amy MacDougall, Savina Jaeger, Magdalena Hofer, Charlie Li, Federico Mingozzi, Tiffany Chang, Gallia Levy

Blood (2022) 140 (Supplement 1): 10662–10664.

https://doi.org/10.1182/blood-2022-159027

Published: 2022

Journal Articles

The Effects of Immunomodulation with Corticosteroids to Manage an AAV Capsid Immune response in the Phase I/II Study of SPK-8011

Matthew S. Evans, Witold B. Rybka, Stacy E. Croteau, Huyen Tran, John E.J. Rasko, Kristen Jaworski, Amy MacDougall, Savina Jaeger, Federico Mingozzi, Tiffany Chang, Gallia Levy

Blood (2022) 140 (Supplement 1): 10654–10655.

https://doi.org/10.1182/blood-2022-159017

Published: 2022

Journal Articles

Transjugular Liver Biopsy in Hemophilia Is Safe with a Minimum of Two Doses of Factor.

Margaret V. Ragni, M.D., Kristen Jaworski, B.S.N., Lisa Boggio, M.D., Doreen B. Brettler, M.D., W. Keith Hoots, M.D., Philip Kuriakose, M.D., Cynthia Jean Rutherford, M.D., Albert B. Zajko, M.D.

Blood (2004) 104 (11): 3078.

https://doi.org/10.1182/blood.V104.11.3078.3078

Published: 2004

Journal Articles

Human Immune Responses to AAV-2 Capsid May Limit Duration of Expression in Liver-Directed Gene Transfer in Humans with Hemophilia B.

Katherine High, MD, Michael Tigges, PhD, Catherine Manno, MD, Denise Sabatino, PhD, Valder Arruda, MD, Roland Herzog, PhD, Pradip Rustagi, MD, John Rasko, MD, Jurg Sommer, PhD, Kristen Jaworski, RN, Margaret Ragni, MD, Bertil Glader, MD, Ruth Lessard, Alvin Luk, PhD, Linda Couto, PhD, Haiyan Jiang, PhD, Glenn Pierce, MD, Mark Kay, MD

Blood (2004) 104 (11): 413.

https://doi.org/10.1182/blood.V104.11.413.413

Published: 2004

NARROW

Long-Term Durable FVIII Expression with Improvements in Bleeding Rates Following AAV-Mediated FVIII Gene Transfer for Hemophilia A: Multiyear Follow-up on the Phase I/II Trial of SPK-8011

Rapid Clearance of Vector Following AAV-Mediated FVIII Gene Transfer in the Phase I/II Trial of SPK-8011 in People with Hemophilia A

The Effects of Immunomodulation with Corticosteroids to Manage an AAV Capsid Immune response in the Phase I/II Study of SPK-8011

Transjugular Liver Biopsy in Hemophilia Is Safe with a Minimum of Two Doses of Factor.

Human Immune Responses to AAV-2 Capsid May Limit Duration of Expression in Liver-Directed Gene Transfer in Humans with Hemophilia B.

Email alerts

ASH Publications

American Society of Hematology

Long-Term Durable FVIII Expression with Improvements in Bleeding Rates Following AAV-Mediated FVIII Gene Transfer for Hemophilia A: Multiyear Follow-up on the Phase I/II Trial of SPK-8011

Rapid Clearance of Vector Following AAV-Mediated FVIII Gene Transfer in the Phase I/II Trial of SPK-8011 in People with Hemophilia A

The Effects of Immunomodulation with Corticosteroids to Manage an AAV Capsid Immune response in the Phase I/II Study of SPK-8011

Transjugular Liver Biopsy in Hemophilia Is Safe with a Minimum of Two Doses of Factor.

Human Immune Responses to AAV-2 Capsid May Limit Duration of Expression in Liver-Directed Gene Transfer in Humans with Hemophilia B.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only